Acrivastina
Acrivastina Uses, Dosage, Side Effects, Food Interaction and all others data.
Acrivastina is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia.
Acrivastina is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.
| Trade Name | Acrivastina |
| Availability | Unknown |
| Generic | Acrivastine |
| Acrivastine Other Names | acrivastina, Acrivastine |
| Type | |
| Formula | C22H24N2O2 |
| Weight | Average: 348.4382 Monoisotopic: 348.183778022 |
| Protein binding | Acrivastine binding to human plasma proteins was 50 ± 2.0%. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Acrivastina is an antihistamine agent used for the symptomatic relief of seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.
For the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.
Acrivastina is also used to associated treatment for these conditions: Seasonal Allergic Rhinitis
Food Interaction
No interactions found.Acrivastina Alcohol interaction
[Moderate] GENERALLY AVOID:
Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.
Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.
Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.
Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
Acrivastina Drug Interaction
Moderate: glycopyrrolateUnknown: aspirin, fluticasone / salmeterol, barium sulfate, celecoxib, dexamethasone, dextran, low molecular weight, dextran, high molecular weight, omega-3 polyunsaturated fatty acids, azelastine / fluticasone nasal, ginkgo, arginine, pregabalin, acetaminophen, budesonide / formoterol, albuterol, cyanocobalamin, ascorbic acid, cholecalciferol, alprazolam
Acrivastina Disease Interaction
Moderate: renal dysfunction, anticholinergic effects, asthma/COPD, cardiovascular
Volume of Distribution
0.46 ± 0.05 L/kg
Elimination Route
Acrivastina was absorbed rapidly from the combination capsule following oral administration and was as bioavailable as a solution of acrivastine. After administration of SEMPREX-D Capsules, maximum plasma acrivastine concentrations were achieved at 1.14 ± 0.23 hour.
Half Life
The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.
Clearance
2.9 ± 0.7 mL/min/kg
Elimination Route
A mass balance study in 7 healthy volunteers showed that acrivastine is primarily eliminated by the kidneys. Over a 72-hour collection period, about 84% of the administered total radioactivity was recovered in urine and about 13% in feces, for a combined recovery of about 97%.
Innovators Monograph
You find simplified version here Acrivastina
